• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

直接胆红素对门肺高压和特发性肺动脉高压的不同影响。

The Different Effects of Direct Bilirubin on Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension.

机构信息

Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.

出版信息

Int J Clin Pract. 2022 Feb 3;2022:7021178. doi: 10.1155/2022/7021178. eCollection 2022.

DOI:10.1155/2022/7021178
PMID:35685569
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9159212/
Abstract

BACKGROUND

To observe different roles of direct bilirubin (Dbil) on portopulmonary hypertension (POPH) and idiopathic pulmonary arterial hypertension (IPAH).

METHODS

Thirty incident patients with POPH and 180 with IPAH (matched by the WHO functional classification in a 1 : 6 ratio) between March 2010 and December 2020 were included. The receiver operating curve and Kaplan-Meier method were applied to estimate the ability to distinguish between the two and survival, respectively. Univariate and forward multiple stepwise regression analyses were performed to access the relationship between pulmonary vascular resistance (PVR) and clinical indices.

RESULTS

Compared to IPAH, the POPH group had better hemodynamics including PVR (7.08 ± 3.95 vs. 14.89 ± 7.11, < 0.001) and higher total bilirubin (Tbil) and Dbil. Tbil and Dbil had a negative correlation with PVR in the POPH group ( = -0.394, =0.031;  = -0.364, =0.048, respectively) but positive correlation in the IPAH group ( = 0.218, =0.003;  = 0.178, =0.018, respectively). Increased neutrophil counts ( = 0.394, =0.031) and elevated NT-proBNP ( = 0.433, < 0.001) would help predict the elevation of PVR in POPH and IPAH groups independent of Dbil, respectively. Dbil could distinguish POPH from IPAH (AUC = 0.799, =0.009), and the ability was elevated when taking aspartate aminotransferase together (AUC = 0.835, < 0.001). The overall survival was better in POPH than in IPAH (7 dead cases of POPH and 96 of IPAH, =0.002). Survival was better in POPH than in IPAH in the group of Dbil ≥7 mol/L (=0.001) but showed no significant difference between POPH and IPAH in the group of Dbil <7 mol/L (=0.192).

CONCLUSIONS

The POPH group had a better hemodynamic profile than IPAH. Dbil was associated oppositely with the elevation of PVR in POPH and IPAH. Patients with POPH had better survival than those with IPAH in the total cohort and in the group of Dbil ≥7 mol/L, but limited dead cases of POPH should be noted.

摘要

背景

观察直接胆红素(Dbil)在门脉性肺动脉高压(POPH)和特发性肺动脉高压(IPAH)中的不同作用。

方法

纳入 2010 年 3 月至 2020 年 12 月期间的 30 例新发 POPH 患者和 180 例 IPAH 患者(按 WHO 功能分类以 1:6 的比例匹配)。应用受试者工作特征曲线和 Kaplan-Meier 法分别估计区分两者和生存的能力。采用单因素和向前逐步多元回归分析评估肺血管阻力(PVR)与临床指标的关系。

结果

与 IPAH 相比,POPH 组具有更好的血流动力学特征,包括更低的 PVR(7.08 ± 3.95 比 14.89 ± 7.11,<0.001)和更高的总胆红素(Tbil)和 Dbil。Tbil 和 Dbil 与 POPH 组的 PVR 呈负相关( = -0.394,=0.031; = -0.364,=0.048,分别),但与 IPAH 组的 PVR 呈正相关( = 0.218,=0.003; = 0.178,=0.018,分别)。增加中性粒细胞计数( = 0.394,=0.031)和升高 NT-proBNP( = 0.433,<0.001)有助于预测 POPH 和 IPAH 组中 PVR 的升高,且与 Dbil 无关。Dbil 可区分 POPH 和 IPAH(AUC=0.799,=0.009),当与天门冬氨酸氨基转移酶联合使用时,其区分能力升高(AUC=0.835,<0.001)。POPH 的总体生存率优于 IPAH(POPH 死亡 7 例,IPAH 死亡 96 例,=0.002)。在 Dbil≥7μmol/L 的组中,POPH 的生存率优于 IPAH(=0.001),但在 Dbil<7μmol/L 的组中,POPH 和 IPAH 之间的生存率无显著差异(=0.192)。

结论

POPH 组具有比 IPAH 更好的血流动力学特征。Dbil 与 POPH 和 IPAH 中 PVR 的升高呈相反关系。在总队列和 Dbil≥7μmol/L 的组中,POPH 患者的生存率优于 IPAH 患者,但应注意 POPH 患者的死亡人数有限。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fc/9159212/f1b76dca255b/IJCLP2022-7021178.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fc/9159212/5235768dccbb/IJCLP2022-7021178.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fc/9159212/0e7c5f757a6d/IJCLP2022-7021178.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fc/9159212/f1b76dca255b/IJCLP2022-7021178.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fc/9159212/5235768dccbb/IJCLP2022-7021178.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fc/9159212/0e7c5f757a6d/IJCLP2022-7021178.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fc/9159212/f1b76dca255b/IJCLP2022-7021178.003.jpg

相似文献

1
The Different Effects of Direct Bilirubin on Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension.直接胆红素对门肺高压和特发性肺动脉高压的不同影响。
Int J Clin Pract. 2022 Feb 3;2022:7021178. doi: 10.1155/2022/7021178. eCollection 2022.
2
Direct bilirubin: A new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension.直接胆红素:特发性肺动脉高压不良预后的一个新危险因素。
Int J Cardiol. 2017 Feb 1;228:895-899. doi: 10.1016/j.ijcard.2016.11.036. Epub 2016 Nov 7.
3
Portopulmonary hypertension: a report from the US-based REVEAL Registry.肝肺高血压:来自美国 REVEAL 注册研究的报告。
Chest. 2012 Apr;141(4):906-915. doi: 10.1378/chest.11-0160. Epub 2011 Jul 21.
4
Portopulmonary hypertension: prognosis and management in the current treatment era - results from the REHAP registry.肝肺高血压:在当前治疗时代的预后和管理 - 来自 REHAP 登记研究的结果。
Intern Med J. 2021 Mar;51(3):355-365. doi: 10.1111/imj.14751.
5
Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry.门脉性肺动脉高压和特发性肺动脉高压中的健康差异与治疗方法:肺动脉高压协会注册研究分析
Pulm Circ. 2021 May 17;11(3):20458940211020913. doi: 10.1177/20458940211020913. eCollection 2021 Jul-Sep.
6
Predictors of Waitlist Mortality in Portopulmonary Hypertension.门静脉高压性肺动脉高压患者等待名单上死亡的预测因素
Transplantation. 2017 Jul;101(7):1609-1615. doi: 10.1097/TP.0000000000001666.
7
The effect of docosahexaenoic acid on predicting the survival of patients with idiopathic pulmonary arterial hypertension.二十二碳六烯酸对预测特发性肺动脉高压患者生存率的影响。
Ann Transl Med. 2021 Jun;9(12):995. doi: 10.21037/atm-21-2479.
8
Noninvasive Monitoring of Severe Pulmonary Artery Hypertension in Atrial Septal Defect Patients: Role of Serum Bilirubin Combined with Uric Acid.房间隔缺损患者重度肺动脉高压的无创监测:血清胆红素联合尿酸的作用
Rev Cardiovasc Med. 2024 Jan 29;25(2):50. doi: 10.31083/j.rcm2502050. eCollection 2024 Feb.
9
Sex Differences in Portopulmonary Hypertension.门脉高压症的性别差异。
Chest. 2021 Jan;159(1):328-336. doi: 10.1016/j.chest.2020.07.081. Epub 2020 Aug 13.
10
Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension.肺血管阻力可预测移植患者合并门脉高压肺血管病患者的死亡率和移植物失功。
Liver Transpl. 2021 Dec;27(12):1811-1823. doi: 10.1002/lt.26091. Epub 2021 Jun 29.

引用本文的文献

1
A nomogram model for predicting maternal cardiovascular complications and neonatal adverse outcomes in pregnant patients with pulmonary arterial hypertension.预测肺动脉高压妊娠患者孕产妇心血管并发症和新生儿不良结局的列线图模型
Ann Med. 2025 Dec;57(1):2541093. doi: 10.1080/07853890.2025.2541093. Epub 2025 Aug 4.
2
Identification of immune-related hub genes and analysis of infiltrated immune cells of idiopathic pulmonary artery hypertension.特发性肺动脉高压免疫相关枢纽基因的鉴定及浸润免疫细胞分析
Front Cardiovasc Med. 2023 Feb 28;10:1125063. doi: 10.3389/fcvm.2023.1125063. eCollection 2023.

本文引用的文献

1
Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry.门脉性肺动脉高压和特发性肺动脉高压中的健康差异与治疗方法:肺动脉高压协会注册研究分析
Pulm Circ. 2021 May 17;11(3):20458940211020913. doi: 10.1177/20458940211020913. eCollection 2021 Jul-Sep.
2
Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension.肺血管阻力可预测移植患者合并门脉高压肺血管病患者的死亡率和移植物失功。
Liver Transpl. 2021 Dec;27(12):1811-1823. doi: 10.1002/lt.26091. Epub 2021 Jun 29.
3
The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan.
日本的门脉肺高压的临床特征、治疗和生存情况。
BMC Pulm Med. 2021 Mar 16;21(1):89. doi: 10.1186/s12890-021-01452-3.
4
Portopulmonary Hypertension: Prevalence, Clinical and Hemodynamic Features.门静脉高压性肺动脉高压:患病率、临床及血流动力学特征
Curr Probl Cardiol. 2021 Mar;46(3):100747. doi: 10.1016/j.cpcardiol.2020.100747. Epub 2020 Nov 4.
5
Portopulmonary Hypertension: From Bench to Bedside.门肺高压:从实验台到病床边
Front Med (Lausanne). 2020 Nov 3;7:569413. doi: 10.3389/fmed.2020.569413. eCollection 2020.
6
Association between splenectomy and portal hypertension in the development of pulmonary hypertension.脾切除术与门静脉高压在肺动脉高压发生过程中的关联。
Pulm Circ. 2020 Mar 31;10(1):2045894019895426. doi: 10.1177/2045894019895426. eCollection 2020 Jan-Mar.
7
Portopulmonary hypertension in the current era of pulmonary hypertension management.当前肺动脉高压管理时代的肝肺高血压。
J Hepatol. 2020 Jul;73(1):130-139. doi: 10.1016/j.jhep.2020.02.021. Epub 2020 Mar 5.
8
Impact of race on survival in pulmonary arterial hypertension: Results from the REVEAL registry.种族对肺动脉高压患者生存的影响:REVEAL 注册研究结果。
J Heart Lung Transplant. 2020 Apr;39(4):321-330. doi: 10.1016/j.healun.2019.11.024. Epub 2020 Jan 24.
9
Portopulmonary hypertension: prognosis and management in the current treatment era - results from the REHAP registry.肝肺高血压:在当前治疗时代的预后和管理 - 来自 REHAP 登记研究的结果。
Intern Med J. 2021 Mar;51(3):355-365. doi: 10.1111/imj.14751.
10
Reply to: "Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia".回复:“在亚洲,酒精性肝病而非乙型肝炎是肝硬化的主要病因”。
J Hepatol. 2019 May;70(5):1033. doi: 10.1016/j.jhep.2019.01.023. Epub 2019 Feb 19.